Abstract
This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
Claims
-
A method for treating a subject having a tumor or cancer, which tumor or cancer overexpresses AKT kinase comprising:
a. administering to said subject:
i. at least one compound of formula I selected from the group consisting of the following compounds:
wherein each R2′, R3′, and R5′ is independently hydrogen; optionally substituted phosphate or phosphonate; mono-, di-, or triphosphate; acyl; lower acyl; alkyl; lower alkyl; amide; sulfonate ester; alkyl sulfonate ester; arylalkyl sulfonate ester; sulfonyl; methanesulfonyl; benzyl sulfonyl, wherein the phenyl group of said benzyl is optionally substituted with one or more halo, hydroxyl, amino, alkylamino, arylamino, alkoxy, aryloxy, nitro, cyano, sulfonic acid, sulfate, phosphonic acid, phosphate, or phosphonate; optionally substituted arylsulfonyl; a lipid; phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group that, in vivo, provides a compound of said formula I wherein R2′, R3′ or R5′ is independently H or mono-, di- or tri-phosphate;
wherein Rx and Ry are independently hydrogen; optionally substituted phosphate; acyl; lower acyl; amide; alkyl; lower alkyl; aromatic; polyoxyalkylene; polyethyleneglycol; optionally substituted arylsulfonyl; a lipid; a phospholipid; an amino acid; a carbohydrate; a peptide; or cholesterol; or other pharmaceutically acceptable leaving group; and
wherein R1 and R2 each are independently H, optionally substituted straight chained, branched or cyclic alkyl, lower alkyl, alkenyl, or alkynyl, CO-alkyl, CO-alkenyl, CO-alkynyl, CO-aryl or heteroaryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonyl, alkylsulfonyl, arylsulfonyl, or aralkylsulfonyl;
wherein the amount of compound of formula I administered to said subject is at least 2 mg/m2.ii. one or more epidermal growth factor receptor inhibitors or a salt thereof; and
iii. a pharmaceutically acceptable carrier,
- The method of claim 1, wherein the compound of formula I is triciribine.
- The method of claim 1, wherein the compound of formula I is triciribine phosphate.
- The method of claim 1, wherein the compound of formula I is triciribine phosphonate.
- The method of claim 1, wherein the compound of formula I is present in a dose amount of at least 20 mg/m2.
- The method of claim 1, wherein the compound of formula I is present in an amount of at least 10 mg/m2.
- The method of claim 1, wherein the administration is parenteral administration.
- The method of claim 7, wherein the parenteral administration is intravenous administration.
- The method of claim 1, wherein the administration is oral administration.
- The method of claim 1, suitable for intravenous administration.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor compound or salt thereof is present in a dose about 0.1 mg/m2 to about 200 mg/m2.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor compound or salt thereof is present in a dose about 1 mg/m2 to about 150 mg/m2.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor compound or salt thereof is present in a dose about 10 mg/m2 to about 100 mg/m2.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor compound or salt thereof is present in a dose about 25 mg/m2 to about 50 mg/m2.
- The method of claim 1, wherein the administration of a compound of formula I and epidermal growth factor receptor inhibitor compound or salt thereof is concurrently administered.
- The method of claim 1, wherein the administration of a compound of formula I is followed by the administration of epidermal growth factor receptor inhibitor compound or salt thereof.
- The method of claim 1, wherein the administration of epidermal growth factor receptor inhibitor compound or salt thereof is followed by the administration of a compound of formula I.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor is gefitinib.
- The method of claim 1, wherein the epidermal growth factor receptor inhibitor is erlotinib.
Owners (US)
-
University Of South Florida
(Jun 08 2015)
Explore more patents:
Applicants
-
Univ South Florida
Explore more patents:
Inventors
-
Cheng Jin Q
Explore more patents:
-
Sebti Said M
Explore more patents:
CPC Classifications
-
A61K31/7064
Explore more patents:
-
A61K9/0019
Explore more patents:
-
A61K9/0053
Explore more patents:
-
A61K31/517
Explore more patents:
-
A61K31/5377
Explore more patents:
-
A61K31/7068
Explore more patents:
-
A61K31/7076
Explore more patents:
-
A61K45/06
Explore more patents:
-
C12Q1/6886
Explore more patents:
-
C12Q2600/106
Explore more patents:
-
C12Q2600/158
Explore more patents:
-
G01N33/57426
Explore more patents:
-
G01N2333/912
Explore more patents:
IPC Classifications
-
A61K31/70
Explore more patents:
-
A61K9/00
Explore more patents:
-
A61K31/517
Explore more patents:
-
A61K31/5377
Explore more patents:
-
A61K31/7052
Explore more patents:
-
A61K31/7064
Explore more patents:
-
A61K31/7076
Explore more patents:
-
A61K45/06
Explore more patents:
Document Preview
- Publication: May 23, 2017
-
Application:
Dec 28, 2015
US 201514998352 A
-
Priority:
Dec 28, 2015
US 201514998352 A
-
Priority:
Nov 27, 2013
US 201314092323 A
-
Priority:
Apr 23, 2012
US 201213453789 A
-
Priority:
May 12, 2008
US 11886108 A
-
Priority:
Mar 29, 2005
US 9608205 A
-
Priority:
Mar 29, 2004
US 55759904 P